JAMA 2 Feb 2011 Vol 305 487 Most of us have never come near a vial of bevacizumab, though we’ve read plenty about it, especially over recent years in the context of eye disease involving vascular proliferation. This monoclonal antibody targeting vascular endothelial growth factor A was initially developed as a treatment for solid cancers […]
Richard Lehman’s journal review – 7 February 2011
